Last reviewed · How we verify

Biological: COVID-19 convalescent plasma — Competitive Intelligence Brief

Biological: COVID-19 convalescent plasma (Biological: COVID-19 convalescent plasma) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Infectious Diseases.

phase 2 Infectious Diseases Biologic Live · refreshed every 30 min

Target snapshot

Biological: COVID-19 convalescent plasma (Biological: COVID-19 convalescent plasma) — Nakhle Saba, MD. COVID-19 convalescent plasma contains antibodies that help the body fight COVID-19 infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Biological: COVID-19 convalescent plasma TARGET Biological: COVID-19 convalescent plasma Nakhle Saba, MD phase 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biological: COVID-19 convalescent plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/biological-covid-19-convalescent-plasma. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: